Explanipedia

Finerenone in patients with severe heart failure: The FINEARTS ‐ HF trial Open

Riccardo M. Inciardi, Henri Lu, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund , et al. · 2025

Aims While patients with severe heart failure (HF) were historically considered to have reduced left ventricular ejection fraction (LVEF), it is increasingly recognized that severe HF occurs across the full spectrum of LVEF. The aim of thi…

Effect of Finerenone on Morbidity and Mortality in CKD Open

John W. Ostrominski, Gerasimos Filippatos, B Claggett, Zi Michael Miao, Akshay S. Desai , et al. · 2025

Key Points In three trials, finerenone reduced a range of cardiovascular and kidney outcomes in persons with diabetes and CKD. Benefits of finerenone were observed across a broad spectrum of glycemia and kidney structure and function. In e…

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Open

Henri Lu, Brian Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund , et al. · 2025

Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics Open

Misato Chimura, Pardeep S. Jhund, Alasdair D Henderson, M. Yang, Brian Claggett , et al. · 2025

Importance Given their kidney actions, it is important to evaluate the efficacy and safety of mineralocorticoid receptor antagonists when combined with other diuretics and whether they have a so-called diuretic-sparing effect in patients w…

Finerenone According to Frailty in Heart Failure Open

Jawad H. Butt, Pardeep S. Jhund, Alasdair D Henderson, Brian Claggett, Chern‐En Chiang , et al. · 2025

Importance Patients with frailty are often perceived to have a less favorable benefit-risk profile for novel therapies and therefore may be less likely to receive these. Objective To examine the efficacy and safety of finerenone, compared …

Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial Open

Mario Berger, Aidan MacNamara, João Pedro Ferreira, Peter Kolkhof, Sebastian Voß , et al. · 2025

International audience

Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index Open

Peter Rossing, Andreas L. Birkenfeld, Paola Fioretto, Janet B. McGill, Stefan D. Anker , et al. · 2025

Key Points Frailty is associated with a higher risk of adverse outcomes in people with CKD and type 2 diabetes. Finerenone reduced the risk of kidney and cardiovascular outcomes irrespective of baseline frailty. Finerenone was well tolerat…

Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Open

Orly Vardeny, Muthiah Vaduganathan, Brian Claggett, Akshay S. Desai, Pardeep S. Jhund , et al. · 2024

Importance Treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), improved outcomes in patients with heart failure with mildly reduced or preserved ejection fraction in FINEARTS-HF, but was associated with i…

Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis Open

Bertram Pitt, Rajiv Agarwal, Stefan D. Anker, Peter Rossing, Luís M. Ruilope , et al. · 2024

Aims Hypokalaemia is associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). This exploratory FIDELITY analysis, a prespecified pooled patient-dataset from FIDELIO-DKD and FIGARO-DKD, investigated…

Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial Open

Kieran F. Docherty, Alasdair D Henderson, Pardeep S. Jhund, Brian Claggett, Akshay S. Desai , et al. · 2024

BACKGROUND: The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patient…

Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies Open

Franz Schaefer, Giovanni Montini, Hee Gyung Kang, Johan Vande Walle, Joshua J. Zaritsky , et al. · 2024

Back Cover Open

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope , et al. · 2023

The outside back cover image is based on the Original Article The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELIT…

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis Open

Sylvia E. Rosas, Luís M. Ruilope, Stefan D. Anker, Bertram Pitt, Peter Rossing , et al. · 2023

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study Open

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope , et al. · 2023

Aim To assess the effect of finerenone on the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, with and without obesity. Materials and methods A post hoc analysis of the prespecified p…

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease Open

Gerasimos Filippatos, Stefan D. Anker, Bertram Pitt, Darren K. McGuire, Peter Rossing , et al. · 2022

Aims Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This subgroup analysis of FIDELITY…

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies Open

Valentín Ortiz‐Maldonado, Susana Rives, María Castellà, Anna Alonso‐Saladrigues, Daniel Benítez‐Ribas , et al. · 2020

Andrea Scalise YOU? Author Swipe